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Effect of life skills building education and
micronutrient supplements provided from
preconception versus the standard of care
on low birth weight births among
adolescent and young Pakistani women
(15–24 years): a prospective, populationbased cluster-randomized trial
Jo-Anna B. Baxter1,2, Yaqub Wasan3, Sajid B. Soofi3, Zamir Suhag3 and Zulfiqar A. Bhutta1,2,3*

Abstract
Background: Risk factors known to impact maternal and newborn nutrition and health can exist from adolescence.
If an undernourished adolescent girl becomes pregnant, her own health and pregnancy are at an increased risk for
adverse outcomes. Offering preconception care from adolescence could provide an opportunity for health and
nutrition promotion to improve one’s own well-being, as well as future pregnancy outcomes and the health of the
next generation.
Methods: The Matiari emPowerment and Preconception Supplementation (MaPPS) Trial is a population-based
two-arm, cluster-randomized, controlled trial of life skills building education and multiple micronutrient supplementation
provided in a programmatic context to evaluate the impact on pre-identified nutrition and health outcomes among
adolescent and young women (15–24 years) in Matiari district Pakistan, and the infants born to them within the
context of the trial. The primary aim is to assess the effect of the intervention on the prevalence of low birth weight
births (< 2500 g). The intervention includes bi-monthly life skills building education provided from preconception, and
supplementation with multiple micronutrients during preconception (twice-weekly), pregnancy (daily), and post-partum
(daily to 6 months). The standard of care includes non-regulated community-based health sessions and daily iron and
folic acid supplementation during pregnancy. Additional outcome information will also be collected at set time periods.
Among participants, these relate to nutrition (anthropometry, nutritional status), morbidity, and mortality. Among infants,
these include birth outcomes (stillbirth, preterm birth, length of gestation, small for gestational age, birth defects),
anthropometry, morbidity, and mortality.
(Continued on next page)
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Discussion: Preconception care from adolescence that includes interventions targeting life skills development and
nutrition is suggested to be important to improving the health and nutrition of adolescent and young women and their
future offspring. This study is expected to offer insight into providing such an intervention both within a programmatic
context and with an extended exposure period prior to conception.
Trial registration: The MaPPS Trial was registered retrospectively on clinicaltrials.gov (Identifier: NCT03287882) on
September 19, 2017.
Keywords: Adolescence, Young adult, Nutrition, Micronutrients, Education, Preconception, Low birth weight, Pregnancy,
Empowerment

Plain English summary
Proper nutrition during pregnancy is important to the
good health of mothers and their infants. However, many
women in low- and middle-income countries who become
pregnant have poor nutrition, and this can affect the outcome of their pregnancies and the health of their infants.
If a well-nourished woman becomes pregnant, she is more
likely to be healthy, have a healthy pregnancy, and give
birth to a healthy infant. In this study, we aim to improve
the nutrition and health of adolescent and young women
(15–24 years) in rural Pakistan before they become pregnant, and so that they might be better nourished before
becoming pregnant. To improve participants’ nutrition
and health, we will provide life skills building education
and multiple micronutrient supplements before they become pregnant and until 6 months after they give birth if
they become pregnant. Because adolescent and young
women in rural Pakistan are known to be undernourished
and have babies early in life, they could benefit from this
intervention. To determine the effect of the intervention,
we will compare it to the care that women normally receive within the existing public health system. The main
measurement that we will compare is how many infants
are born with a birth weight that is low (< 2500 g), which
suggests that the infants did not grow well during the
pregnancy. Ultimately, we hope that the findings from
this study will help us to understand what care should
be given to women in places with poor nutrition before
they become pregnant so that they have healthier
pregnancies.
Background
While the focus of global public health experts has been
on the first 1000 days of life as the most developmentally
critical period, risk factors known to impact maternal
and newborn health can exist from adolescence [1]. If an
adolescent girl becomes pregnant, her pregnancy is at an
increased risk for adverse outcomes, including preterm
birth and low birth weight (LBW) [2]. Furthermore,
births to adolescent mothers can negatively affect both
the mother and infant’s health in the future [3, 4]. As
approximately 11% of all births are to adolescents

15–19 years of age, and more than 90% of these occur in
low- and middle-income countries (LMICs), providing appropriate interventions prior to and during pregnancy will
be crucial to reducing the burden of adverse outcomes [5].
Antenatal care (ANC) services offer an opportunity for
maternal screening and intervention during pregnancy.
However, in LMICs women tend not to report for care
until the second trimester [6], thus the initial 100–150 of
the first 1000 days are frequently missed. This presents a
major limitation to ensuring adequate uptake of interventions for a reasonable duration, even though factors like
nutritional status are crucial from the time of conception
for placentation, organogenesis, prevention of congenital
birth defects, and fetal growth [7–9]. Given the risks associated with anemia during pregnancy, iron and folic acid
(IFA) supplementation is the standard of care during
ANC [10]. Many experts have come to suggest that multiple micronutrient (MMN) supplementation should replace IFA given the prevalence of MMN deficiencies in
LMICs, multiple causes of anemia, and synergistic interactions between micronutrients within biological processes
[6, 11]. MMN supplementation during pregnancy can significantly decrease the risk of LBW births (relative risk:
0.88; 95% confidence interval: 0.85 to 0.91; high-quality
evidence) compared to IFA [12], and among undernourished and anemic pregnant women MMN supplements
could further improve infant survival and birth outcomes
[13]. At this time, MMN supplementation has been neither accepted nor recommended by the World Health
Organization [10].
Offering preconception care from adolescence could provide an opportunity for health and nutrition promotion to
improve one’s own well-being, as well as future pregnancy
outcomes and the health of the next generation [14]. Including a life skills building education (LSBE) component
around empowering adolescent and young women to make
informed health-related decisions will be key to sustainable
and proficient uptake [14], as will be addressing underlying
MMN insufficiencies [15]. Currently, there is a paucity of
well-designed, interventional trials around the provision of
MMN supplements preconceptionally. There are 4 existing
trials which aim to investigate the efficacy of different
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preconception MMN supplements on birth outcomes
within a trial setting (Table 1) [16–19]. Among the completed studies, the extent to which preconception MMN
supplementation has affected each study’s respective primary outcome is variable.
We hypothesize that the programmatic provision of
LSBE and MMN supplements in a population-based setting in rural Pakistan will improve selected health, nutrition, and pregnancy-related outcomes among adolescent
and young women 15–24 years old compared to those
who receive the standard of care. For those who receive
the intervention prior to and during pregnancy, we expect that there will be a decrease in the prevalence of
LBW births. Conducting this trial within the context of
the existing Pakistani public health program, we will assess the effectiveness of the intervention.

within the context of the trial. Depending on whether participants become pregnant or not, there are three phases:
preconception (maximum 24 months in duration); pregnancy (approximately 9 months in duration); and postpartum (maximum 12 months in duration). A detailed trial
protocol has been developed in accordance with the SPIRIT
guidelines [20] in a collaboration between the Aga Khan
University (AKU; Karachi, Pakistan) and the Hospital for
Sick Children (Toronto, Ontario, Canada). This paper addresses the methods for the pregnancy and postpartum
phases of the MaPPS Trial, with the methods for ongoing
measures taken throughout the preconception phase
among participants who do not become pregnant appearing elsewhere [21].
The first participant was enrolled on 30 June 2017;
enrolment is expected to be ongoing until July 2018; and
planned data collection will continue until 2021.

Methods
The Matiari emPowerment and Preconception Supplementation (MaPPS) Trial is a two-arm, cluster-randomized,
controlled trial of LSBE and MMN supplementation provided in a programmatic context to evaluate the impact on
pre-identified nutrition and health outcomes among adolescent and young women, and the infants born to them

Objectives

The primary aim of the pregnancy and postpartum phases
of the MaPPS Trial is to evaluate the impact of LSBE
(provided bi-monthly) and supplementation with MMN
(preconception: twice-weekly; pregnancy: daily) versus the
standard of care (non-regulated community-based health

Table 1 Summary of ongoing and completed interventional trials investigating preconceptional multiple micronutrient
supplementation
Study name

Years active

Country

No. arms

Intervention

Minimum exposure
to intervention

Potdar 2014 [16]
(Mumbai Maternal
Nutrition Project)

2006–2011

India

2

Arm 1: preconception: daily
micronutrient-rich food snack;
pregnancy: daily micronutrient
rich food snack
Arm 2: preconception: daily
micronutrient-poor food snack;
pregnancy: daily micronutrient
poor food snack

3 months

Hambidge 2014 [17]
(Women First Study)

2013– ongoing

multi-site
(Congo, Guatemala,
India, Pakistan)

3

Arm 1:
preconception: daily MMN
via lipid-based nutrient
supplements (LNS)
pregnancy: daily MMN via LNS
Arm 2:
preconception: none
pregnancy: daily MMN via LNS
Arm 3:
preconception: none
pregnancy: none

3 months

Owens 2015 [18]

2006–2008

The Gambia

2

Arm 1: preconception: daily
UNIMMAP preparation tablet;
pregnancy: daily IFA tablet
Arm 2: preconception: placebo
control; pregnancy: daily IFA tablet

not specified

Ramakrishnan2016 [19]
(PRECONCEPT)

2011–2013

Vietnam

3

Arm 1: preconception: weekly MMN
tablet; pregnancy: daily IFA tablet
Arm 2: preconception: weekly IFA
tablet; pregnancy: daily IFA tablet
Arm 3: preconception: weekly FA
tablet; pregnancy: daily IFA tablet

not specified
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sessions; preconception: no supplementation; pregnancy:
daily IFA supplementation) on the prevalence of LBW
births (< 2500 g). There are several secondary objectives
for participants enrolled in the trial and the infants born
to them to further determine the effect of LSBE and
MMN supplementation compared to the standard of care.
Among participants, these relate to nutrition (anthropometry
[height, weight, middle upper arm circumference (MUAC)],
nutritional status [iron, vitamin A, vitamin D]) and general
health (e.g., morbidity, mortality). Among infants born to
participants, secondary objectives include assessing the
effect on birth outcomes (stillbirth, preterm birth,
length of gestation, small for gestational age, birth defects), anthropometry (weight, length, MUAC, head circumference [HC]), morbidity, and mortality.
Setting and participants

The MaPPS trial will be conducted in rural settings within
Matiari district in Sindh province, Pakistan. Matiari is situated in the north-eastern part of Sindh, about 200 km
away from Karachi, and representative of typical conditions in rural Pakistan. Including 1418 villages and a
population of about 776,000, around 78,000 residents are
adolescent and young women 15–24 years (based on regular surveillance data).
The nutritional status of Pakistani women is suggested
to be suboptimal, and often attributed to that dietary staples are micronutrient poor [22, 23]. A comparable number of non-pregnant and pregnant women are anemic
(51%) and experience iron deficiency anemia (20 and
26% among non-pregnant and pregnant women, respectively); deficiencies in other micronutrients are also
common (e.g., vitamin A [43 and 49%] and vitamin D
[85 and 86%]) [22]. Infants born to Pakistani women
are consequently at an increased risk of poor growth
and development. The national prevalence of LBW is
26%, yet this is higher among young mothers (29%) and
in rural areas (33%) [23].
This trial is situated within Pakistan’s National Program
for Family Planning and Primary Health Care as part of
the Lady Health Worker (LHW) Programme. The LHW
Programme aims to provide essential primary health
services in the community using a cadre of female community health workers called LHWs [24]. Each LHW is
affiliated with a health facility, where she reports to her
lady health supervisor (LHS), and is responsible for approximately 1000 people in the community. LHWs visit
the homes in their catchment area monthly and carry
out community support sessions to disseminate health
education messages [25]. The priority age groups for
LHWs are children < 5 years, pregnant women, and
couples eligible for family planning, thus the content of
existing LHW educational materials primarily focuses
on the health of married women and children [24].
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Eligibility criteria

As the MaPPS Trial is a population-based effectiveness
study of LSBE and MMN supplementation from preconception, broad eligibility criteria for participation in the
preconception phase were established to improve the
generalizability of the trial findings. Specifically, this includes that the minimum age at enrolment is 15 years
and the maximum age is 23 years, such that participants
will not age out of the trial prior to conception; adolescent and young women must report to be physically
able to comply with the trial intervention. Adolescent
and young women are not eligible to enrol if they are
currently pregnant (to be re-approached after giving
birth), participating in a different nutrition trial, or intend to leave the trial area. They can be of any marital
status.
To proceed to the pregnancy phase of the MaPPS
Trial, participants will be included if they become pregnant within 24 months of recruitment. To ensure adequate exposure to the intervention, only women who
become pregnant after 6 months of MMN supplementation will be formally considered a part of the per-protocol
MaPPS pregnancy phase. To maintain the relationship
with the local community, women in the intervention
arm who become pregnant prior to 6 months of
MMN supplementation will be retained in the trial
and some routine data will be collected on them and
their pregnancies. To further be included in the postpartum phase of the MaPPS Trial, a woman will have
to have had a live birth.

Design and sample size

The MaPPS Trial is a two-arm, parallel, prospective,
cluster-randomized, controlled trial (Fig. 1). A clusterrandomized design was chosen to prevent contamination
between the control and intervention arms through supplement sharing. The unit of randomization is previously
defined and mapped health facility clusters, where health
care services are provided to the surrounding population. A total of 26 clusters are available to be randomized (i.e., 13 clusters per arm). PASS 11 Software (NCSS,
LLC., Kaysville, UT, USA) was used to determine all
sample size calculations.
To observe a 25% relative reduction in LBW births
(the a priori minimum detectable difference of public
health importance for this trial) among pregnant
women 15–24 years, assuming a 30% prevalence of LBW,
icc = 0.011, k = 0.16, accounting for 10% attrition and
probability of type I and type II errors of 0.05 and
0.20, respectively, the number births required per
cluster was 56. This equates to 728 births per arm.
To achieve these births, 12,712 women per arm will
be required (total: 25,424 women).

Baxter et al. Reproductive Health (2018) 15:104

Page 5 of 13

Fig. 1 Matiari emPowerment and Preconception Supplementation (MaPPS) Trial flow diagram

Cluster randomization and allocation concealment

The cluster allocation sequence was generated by an independent statistician (Simon Cousens, London School
of Hygiene and Tropical Medicine) using a computergenerated stratification sequence in Stata software
(StataCorp, College Station, TX, USA) based on the available health facilities in the district. The list was provided
to the study manager, as full blinding is not possible given
the nature of implementation of the intervention and control. Participants and LHWs are also not blinded given the
differences between the intervention and control. The primary investigator, co-investigators, data collectors, phlebotomists, laboratory personnel, and data analysts are
blinded to arm allocation. The allocation sequence will be
provided to the trial Data Safety and Monitoring Board
(DSMB) in cases where individual participants need to be
unblinded given a suspected MMN supplement-related
adverse events.
Intervention and control
LSBE materials

In intervention clusters, enhanced LSBE materials have
been developed on topics important to the empowerment
of adolescent and young women to complement the existing LHW materials for use in community sessions. These

will be implemented bi-monthly and attendance will be
recorded. Three topic areas were prioritized: (a) delaying
early marriage; (b) practicing appropriate personal and
menstrual hygiene; and (c) the importance of good nutrition to health. Approximately 20 min is intended to be
spent on each topic at community sessions. Integrated
throughout the 3 topics are messages related to continuing one’s education, mental health (how to cope with
stress, anxiety, and when you are upset), gender norms
and equality, decision-making, advocacy, resiliency, participation, communication skills, facing challenges, agency,
conflict resolution, and the prevention of violence.
Communication tools have been developed to assist the
LHWs in conducting the LSBE-based community sessions. These were developed in coordination with Aahung,
a Karachi-based non-governmental organization that aims
to improve the sexual and reproductive health of girls
(www.aahung.org; Karachi, Pakistan). Communication tools
include a flipchart with 2 pictorials and discussion prompts
per topic for use in sessions; and a brief summary pamphlet
for distribution to participants. The flipcharts are similar to
existing LHW tools for leading community sessions. A
team of master trainers will be trained on all LSBE materials and appropriate communication techniques. The master trainers, in turn, provide comprehensive and interactive

Baxter et al. Reproductive Health (2018) 15:104

training for all intervention LHWs. Refresher training will
also be provided on an ongoing basis throughout the duration of the trial.
Trial supplements

The MMN supplements used within the intervention
arm of the MaPPS Trial are consistent with the
UNICEF/WHO/UNU international multiple micronutrient
preparation (UNIMMAP), and have been procured from
the UNICEF Supply Catalogue (https://supply.unicef.org).
Each tablet is 10 mm in diameter and includes vitamin A:
800 μg; vitamin D: 5 μg; vitamin E: 10 mg; folic acid:
400 μg; vitamin B1 (thiamine): 1.4 mg; vitamin B2 (riboflavin): 1.4 mg; vitamin B3 (niacin): 18 mg; vitamin B12:
2.6 μg; vitamin B6: 1.9 mg; vitamin C: 70 mg; iron: 30 mg;
zinc: 15 mg; iodine: 150 μg; copper: 2000 μg; selenium
65 μg (Micronutrient Tabs, Pregnancy; Lomapharm,
Emmerthal, Germany). All MMN supplements are maintained and stored by the study manager in a locked study
office that is temperature controlled. A supply of MMN
supplements is provided to LHWs monthly by a study
monitoring team, which is unblinded to the allocation of
the intervention and not involved in data collection. Once
provided to participants, MMN supplements are stored in
marked, opaque containers labelled with the participant’s
ID and supplement batch number and expiry date.
The IFA supplements are provided to the control arm
as part of Pakistan’s National Program for Family Planning
and Primary Health Care free of charge [24]. Each tablet is
required to include iron and folic acid amounts consistent
with WHO recommendations (i.e., 60 mg of elemental
iron and 400 μg of folic acid) [26].
Balanced-energy and protein (BEP) supplements will also
be provided to those in the intervention and control arm if
participants have a body mass index (BMI) < 18.5 kg/m2
during pregnancy, as per WHO recommendations [10].
Each sachet weighs 75 g and includes energy: 360 kcal; total
fat: 24.8 g; carbohydrates: 19.5 g; protein: 9.9 g; sodium:
82.2 mg; potassium: 406.3 mg; vitamin A: 3.8 μg; vitamin C:
1.3 mg; calcium: 202.1 mg; iron: 0.87 mg (Afzaaish; Ismail
Industries Ltd., Balochistan, Pakistan).
Supplement administration - intervention arm (MMN)

Upon enrolment in the trial, intervention arm LHWs will
visit new participants within one month to provide the
MMN supplements. A participant’s personal supply of
MMN supplements will be monitored and replenished
every month by her respective LHW throughout her enrolment in the trial. If a participant does not become pregnant
within the context of the trial, she will take the MMN
supplements for 24 months (the maximum duration of the
preconception phase; majority of participants). If a participant becomes pregnant within the context of the trial, she
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will take the MMN supplements until 6 months
postpartum.
During the preconception phase, participants are asked
to consume 1 MMN tablet 2 days/week. To make the
incorporation MMN supplementation into their routine
easier, participants are requested to choose a consistent
time on 2 days in the week that are separate from each
other (e.g., Monday and Thursday, or Wednesday and
Saturday) on which to take 1 MMN tablet with a glass of
water and a meal. Each participant is provided with a
1 month supply of MMN supplements, plus a spare week
in case of unscheduled missed visits. As such, participants
receive 10 MMN tablets/month (4 weeks/month × 2
tablets/week + 2 extra tablets = 10 tablets total). During
the pregnancy phase and for the first 6 months during
the postpartum phase, participants are asked to consume 1 MMN tablet/day, given the higher daily micronutrient requirements [27]. As such, these participants
received 38 MMN tablets/month (31 days/month + 7
extra tablets = 38 tablets total).
Participants are instructed that the MMN supplements
are just for them and should be kept away from children.
They are asked to ensure that the lid of the supplement
bottle is tightly closed when not in use and stored away
from light and humidity. It is also explained that some
people experience mild side effects when they start
taking the MMN supplements (e.g., nausea, vomiting,
diarrhea, stomach pains), but that taking it with food
should make side effects less likely to happen. If they
miss a dose, participants are instructed that they
should take 1 MMN tablet the next time that they remember, but never to consume more than 1 MMN
tablet/day. If a participant has any side effects, is concerned, or has questions, she is instructed to contact her
LHW and not study personnel since study personnel
are blinded to whether participants are in the control
or intervention arm. Participants are also asked not
to take non-trial administered supplements while they
are enrolled in the trial.

Supplement administration - control arm (IFA)

If a participant is in a control cluster, IFA supplements
will be administered within 1 week of confirmation of a
pregnancy. Daily IFA supplementation is part of the standard of care during pregnancy in Pakistan, thus LHWs are
asked to continue their usual counselling. As the LHW
program-supplied IFA supplements come in blister packs,
blister packs will be cut up to aid monitoring so that participants receive 38 IFA tablets/month (31 days/month + 7
extra tablets = 38 tablets total), thus matching the method
of provision for the MMN supplements. As in the intervention arm, a participant’s personal IFA supplement supply is monitored and refilled every month by her respective
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LHW. Daily IFA supplementation is to continue until
6 months postpartum.
Supplement administration – Both arms (BEP)

Participants in the intervention and control arm with a
BMI < 18.5 kg/m2 will additionally be provided with
daily BEP sachets for the duration of their pregnancy.
Consistent with the other supplements consumed during
pregnancy, BEP sachets will be provided and monitored
monthly by LHWs (38 BEP sachets/month).
Household listing

To identify young women who may be eligible to participate in the MaPPS Trial, a household-level listing of those
living in LHW-covered areas of Matiari district was completed. The household listing step is consistent with AKU’s
existing surveillance program within Matiari district, and
took place from December 2016 – May 2017. It allowed
for enumeration of the trial population and identification
of young women who met the age criteria for enrolment.
Adolescent and young women who met the age criteria
were further asked questions to determine their potential
eligibility (i.e., screening questions about their intention to
remain in the trial area; involvement in other nutrition trials; and any complicated medical conditions that might
prevent them from being able to take MMN tablets).
Enrolment

Adolescent and young women identified in the household
listing as provisionally eligible are further contacted by
study data collectors at their homes to confirm their
potential interest and eligibility. Provisionally eligible participants will be invited to participate in the preconception
phase of MaPPS Trial in conjunction with their family
members and/or husbands, and data collectors will
explain the purpose and voluntary nature of the trial;
participation components; and potential benefits and
harms prior to obtaining written informed consent. If
participants are < 16 years of age, assent will also be
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obtained as necessary. It is anticipated that enrolment
will take at least 1 year.
Upon enrolment in the trial, a questionnaire designed
to collect information on demographics; socioeconomic
status (SES); reproductive health and history; life skills,
empowerment, and social determinants of health
(SDH)-related factors (Table 2); supplementation practices; and access to LHWs will be administered. The
questionnaire has been adapted from the existing
demographic health survey for Pakistan and several
standardized assessment tools. All participants will also
undergo anthropometric (height, weight, MUAC) and
hemoglobin concentration measurement.
Visit schedule

All visits with trial participants will occur at their
homes. Each phase of the trial has a different number
of visits, depending on how long the participant
remains in the respective phase. Participants who do
not become pregnant within the context of their
enrolment will be followed maximally for 24 months in
the preconception phase. The majority of participants are
expected to fall into this category, and the ongoing
measurements collected during this time are described in
detail elsewhere [21].
Participants will be instructed about the appropriate
signs to recognize pregnancy (e.g., amenorrhea), and
amenorrhea will be assessed at monthly LHW visits.
Women who become pregnant or suspect they may be
pregnant will be asked to contact study personnel or
their LHW, such that pregnancy confirmation might
occur. Depending on when a participant becomes pregnant, her exact length of time in the preconception
phase will vary. Upon confirmation of pregnancy, participants will be followed through to delivery. Participants
and their family members will be asked to contact study
personnel when labour begins. Furthermore, as LHWs
will visit with participants at least monthly for the
duration of the trial and study personnel will visit at set
times, good rapport will be established between

Table 2 Factors relating to life skills, empowerment, and SDH captured within trial questionnaires
Domains

Includes information pertaining to

Evaluation tool

Nutrition

Household food insecurity

Household Food Insecurity Access Scale [30]

Health

Eating habits
Body image
Physical activity

Health Behaviour in School-aged Children [31]

Perception of support

Family, peer, and school

Multidimensional Scale of Perceived Social Support [32]

Decision making

Family, food, health care, and daily needs

Pakistan Demographic Health Survey [23]

Psychosocial health

Self-efficacy
Stress
Mental health (depression, anxiety, and stress)

Generalized self-efficacy scale [33]
Perceived stress scale [34]
Depression, Anxiety, and Stress Scale-21 [35]

Violence

Intimate partner violence
Exposure to violence

Conflict Tactics Scale [36]
Pakistan Demographic Health Survey [23]
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participants, their families and communities, LHWs, and
study personnel, and all will be sensitized to notify of
births as soon as possible. There are several additional
measures to capture birth-related outcomes in a timely
manner, including having personnel dedicated to keeping
in phone contact with the participant close to her due
date and employing a standby birth surveillance team,
which is on call on holidays and weekends. Women who
give birth to a live infant will proceed to the postpartum
phase. Mothers and their infants will be followed until
1 year postpartum.
There will also be ongoing participant monitoring for
the duration of the trial. Upon trial completion or withdrawal, participants will be asked to complete an exit
questionnaire designed to assess their perception of their
own health, the health of their infant, and satisfaction
with trial participation.
Pregnancy phase

Given the frequent contact with and monitoring of participants, it is anticipated that most pregnancies will be
recorded in the first trimester. Suspected pregnancies
will be confirmed using a pregnancy test (HCG Rapid
Test; ImuMed, Bammental, Germany) provided by a participant’s LHW. Confirmation of a pregnancy triggers
completion of the first trimester assessment (Table 3).
This includes formal collection of information on the
participant’s last menstrual period, anthropometry (height,
weight, MUAC), and mental health (Edinburgh Postnatal
Depression Score [EPDS]) [28] by data collectors. All
participants will also be asked to undergo a 5 mL blood

draw. If a participant is found to have a BMI < 18.5 kg/m2,
she will be provided with BEP supplements. Participants
will be encouraged to go to the most convenient public
sector health facility to obtain an ultrasound within 1 week
of contact with data collectors. Among those who obtain
ultrasounds, data will be collected on crown-to-rump
length, estimated age, and general observations (fetal visibility, multiple pregnancy, heart activity, signs of abnormality).
At 32 weeks of gestation, participants will undergo a repeat
anthropometric (height, weight, MUAC) and mental health
(EPDS) assessments.
Postpartum phase Mothers and newborns will be visited within 24 h of birth to obtain anthropometric measurements of the newborn (weight, length, MUAC, HC),
assess of the status of the newborn (e.g., birth defects),
and interview the mother about the birth (Table 4). At
1 week postpartum, maternal status, complications
during labour and delivery, and prelacteal and early
breastfeeding practices will be assessed. Maternal anthropometric measurements (height, weight, MUAC)
and a 5 mL blood draw will also be obtained. At
28 days postpartum, infant assessments will include morbidity and anthropometry (weight, length, MUAC, HC).
Ongoing infant anthropometric and feeding assessments
(breastfeeding and complementary feeding practices) will
be conducted tri-monthly until the end of the trial (i.e., at
3, 6, 9, and 12 months). Maternal mental health (EPDS)
and anthropometric assessments will be reassessed at 3
and 6 months postpartum, respectively.

Table 3 Enrolment and pregnancy phase data collection and measurement activities
Activity

Enrolment

Pregnancy

0m

1st trimester

3rd trimester

Consent

X

Demographics and SES

X

Reproductive health and history

X

Life skills, empowerment, and SDH

X

Mental health

X

X

X

Anthropometry

X

X

X

Hemoglobin

X

X

Serum ferritin

M

X

Hepcidin

M

X

Transferrin receptor

M

X

Infection indicators (CRP, AGP)

M

X

Vitamin A

M

X

Vitamin D

M

X

Pregnancy confirmation

X

Ultrasound assessment

X

X: all participants; M: micronutrient status subgroup participants only
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Table 4 Postpartum phase data collection and measurement activities
Activity

Timing
24 h

1w

1m

3m

6m

9m

12 m

Maternal
Anthropometry

X

Birth history

X

X

Life skills, empowerment, and SDH

X

Mental health

X

Hemoglobin

X

Serum ferritin

X

Hepcidin

X

Transferrin receptor

X

Infection indicators (CRP, AGP)

X

Vitamin A

X

Vitamin D

X

Infant
Anthropometry

X

Clinical assessment

X

Feeding assessment

X

Morbidity

X

X

X

X

X

X

X

X

X

X

X: all participants

LHW visits

Questionnaires

Because LHWs are required to visit households in their
catchment area monthly, these visits will serve to monitor menses, new marriages, and suspected pregnancies
throughout the duration of the trial, in addition to their
mandated function [24]. All trial-administered supplement provision and consumption will also be recorded
at these visits.

For data collector-conducted visits with participants, tablets
(Samsung Galaxy Tab. A T285; Samsung, Vietnam) will be
used to collect questionnaire data. The tablets run a
custom-made data collection application, which includes
built-in logic and range checks, developed using Java
(Oracle Corporation, Redwood Shores, CA, USA) and
MySQL Lite (Oracle Corporation). LHW monitoring visits
will use paper-based questionnaires given the large number
of LHWs involved in the trial.

Adherence, morbidity, and mortality monitoring

All participants will further be visited by an independent
surveillance team to collect morbidity and self-reported adherence data every 3 months (Table 5). These visits will also
allow for the observance and collection of data on non-trial
administered nutritional supplement consumption.
Data collection

Data collection tools have been customized for each type of
visit, and data is collected orally given the low literacy rates
in the trial population. Trained study personnel will collect
all trial outcome data using questionnaires, anthropometric
measurements, and point-of-care tests. Standardized operating procedures have been developed for all measures
in an effort to make data collection practices consistent.
Extensive training sessions will be provided, employing
classroom-based lectures, videos, hands-on practice, and
mock interviews. As appropriate, training will be led by
experienced personnel within the broader AKU network
(e.g., data management unit, laboratory).

Table 5 Monitoring data collection activities ongoing
throughout the trial
Measurement

Monthly
(LHW)

Adherence by pill counta

Quarterly
(Monitoring Team)

ib
c

Adherence by self-reported frequency

ib

Side effects

X

Acceptability

ib

Morbidity (maternal and/or infant)

X

Mortality (maternal and/or infant)

X

X: all participants; i: intervention group only
a
Adherence by pill count defined as number of tablets apparently consumed/
number of possible supplements consumed given days enrolled in the study
b
Among those women who become pregnant in the control group, measure
will also be monitored at the indicated intervals from time of confirmation of
pregnancy until 6 months postpartum
c
Adherence options by self-report during preconception include twice weekly,
intermittently, or not at all; during pregnancy and postpartum include daily,
on alternate days, intermittently, or not at all
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Anthropometric measurements

Data management

For participant measurements, height will be measured
using a stadiometer (seca 213; seca, Hamburg, Germany);
weight using a digital floor scale (seca 813); and MUAC
using a measuring tape (seca 201). For infant measurements, length will be measured using an infantometer
(seca 417), weight using an infant weigh scale (seca
354), and MUAC and HC using a measuring tape
(seca 201 and 212, respectively). All measurements will be
conducted in duplicate by two data collectors. In the
case that two measurement exceed the allowable difference (length: < 1.0 cm; weight: < 0.5 kg; HC: < 0.5 cm;
MUAC: < 0.5 cm), a third measurement will be obtained.
The average (mean) of acceptable paired measures will be
used in analysis. Standardized operating procedures for
the anthropometric measurements were adapted from
published reference materials [29].

Data collection tablets are collected from study personnel
on a daily basis so that questionnaire data can be uploaded
to the AKU data management unit via a remote server
(Windows Server 2008 R2; Microsoft, Redmond, WA,
USA). Questionnaire data collected on paper-based forms
are visually checked by field site supervisors for completeness before being sent to the AKU data management unit
on a weekly basis for entry into a database. Double data
entry is used to reduce data entry errors. The database was
designed using MySQL software and entered using Visual
FoxPro software (Microsoft). All collected data is kept
under lock and key, and anonymized through the use of
nine-digit participant identification codes. Data entered into
the database is password protected.

Point-of-care hemoglobin assessment

To assess hemoglobin concentration, the HemoCue® Hb
301 System (HemoCue; Ängelholm, Sweden) will be used
from blood collected via finger prick.

Outcome measures

To determine the prevalence of LBW at delivery, the primary outcome measure is birth weight < 2500 g. LBW will
then be subdivided into very LBW (< 1500 g) and extremely
LBW (< 1000 g). There are many additional secondary outcome measures within the trial related to nutrition and
health that will be also assessed (see Additional file 1).

Blood specimen collection and laboratory analyses

Statistical analysis

Trained phlebotomists (blinded to cluster allocation) will
conduct all blood specimen collection using standard
sampling procedures developed by the AKU Nutrition
Research Lab (NRL). At each sampling time point, 5 mL
of venous blood will be collected and stored in trace
element-free vacutainer tubes (royal blue top; Greiner
Bio-One, Monroe, NC, USA). Two drops of whole blood
are immediately taken from the collection tube to assess
hemoglobin concentration using the HemoCue® Hb 301
System point of care test. Because all blood specimens
are collected at participants’ homes, they are then stored
in a cool box with ice packs to maintain a temperature
of 2–8 °C and protected from light exposure immediately after sample collection. Whole blood samples are
received at the Matiari field site lab within 4 h, where
the vacutainers are centrifuged to separate the serum
from the red blood cells. The serum is pipetted into
1.8 mL cryovials (red top; Thermo Fisher Scientific,
Waltham, MA, USA) and covered in aluminium to protect from light exposure. The cryovials are then stored
between 2 and 8 °C, and transported in a cool box maintained at 2–8 °C to the AKU NRL once per week. Upon
arrival at the AKU NRL, samples are analysed or stored in
an ultra-low freezer maintained at − 70 °C for future use.
Samples will be assessed for markers of nutritional status
(iron [ferritin, transferrin receptor, hepcidin], vitamin A
[retinol], and vitamin D [25(OH)D]) and inflammation
(c-reactive protein, alpha-1-acid glycoprotein; Table 6).

For the primary outcome, the prevalence of LBW births
will be compared by intervention arm, irrespective of
maternal preconception supplementation duration or adherence (intention-to-treat). The per-protocol analysis will
consider only those women with ≥6 months of exposure
to the intervention. Because the prevalence of anemia and
LBW are high in the trial population, an individual-level
analysis using generalized estimating equations (GEE) will
be employed to determine the estimate of the population
average. Clustering will be accounted for within the GEE
analysis. Sub-analyses will also be conducted, including
determining whether there is a difference among those
who received BEP and those who did not within and between arms, and whether there was a difference between
adolescent and young women. There are several potential
determinants which will be considered as covariates, such
as age, parity, adherence, and SES. Relevant information
will be collected at enrolment and throughout follow-up.
Summary estimates (e.g., means, proportions, counts)
will be reported with 95% confidence intervals. Dichotomous outcomes will be compared using risk ratios
with 95% confidence intervals, and the difference in
continuous variables will be determined by comparing
means. P values less than 0.05 will be considered statistically significant. Statistical analyses will be conducted using Stata software. The plan for the analysis
of secondary objectives and outcome measures will be
presented elsewhere.
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Table 6 Assays and instruments used to determine constituents of interest from collected blood specimens
Micronutrient

Amount of serum (μL)

Assay method

Instrument used

Ferritin

200

Immunoturbidimetric assay method

Cobas C311 Analyzer,
Roche Diagnostics

Transferrin receptor

200

Immunoturbidimetric assay method

Cobas C311 Analyzer,
Roche Diagnostics

Hepcidin

150

Enzyme-linked immunosorbent assay (ELISA)

Hepcidin-25, Bachem

Vitamin A (retinol)

200

Quantitative-high performance liquid
chromatography photodiode array detection

Agilent HPLC, 1200/1260 Infinity
Series with UV/PDA detection

Vitamin D (25(OH)D)

400

Electrochemiluminescence protein binding assay

Diasorin Analyzer, LIAISON

C-reactive protein

200

Immunoturbidimetric assay method

Cobas C311 Analyzer,
Roche Diagnostics

Alpha-1-acid glycoprotein

200

Immunoturbidimetric assay method

Cobas C311 Analyzer,
Roche Diagnostics

Iron

Inflammation

Study management

The field research team is overseen by the study manager,
and includes several different positions (Fig. 2). Of note,
data collection and food recall teams are responsible for
collecting most primary and secondary outcome data; surveillance teams collect morbidity and supplement adherence data, as well as ongoing tracking of pregnancies
and births; and monitoring teams are dedicated to coordinating with LHWs and conduct ongoing data collection
quality checks. A DSMB has been developed including
external international members with expertise in a wide
array of related disciplines (pediatric and adolescent
medicine, statistics, and nutrition). These individuals will
provide expertise and recommendations relating to accumulated data about study operations and participant
safety. When appropriate, they may be asked to make recommendations relating to continuation, modification, or
termination of the trial. The DSMB meets with the study
principal investigator and co-investigators to discuss progress on a quarterly basis.

Fig. 2 Organization of MaPPS Trial field research team

Discussion
Malnutrition prior to and during pregnancy can have
important consequences for survival, acute and chronic
disease incidence, healthy development, and economic
productivity [8]. In this trial, we aim to assess the effectiveness of providing LSBE and MMN supplements to
adolescent and young women in rural Pakistan from
preconception, and compare this intervention with the
standard of care on the prevalence of LBW births. Including a culturally-tailored educational piece aimed at
empowering participants to make informed decisions
about their health and well-being will be key to sustained
behavioural change throughout the life-course. By implementing the intervention within the LHW Programme,
we aim to gather important insight around how to achieve
coverage within the existing programmatic context. This
trial is distinctive in that it recruits both married and unmarried adolescent and young women. Consequently, we
will be better able to ascertain the effect of the intervention on in the context of pregnancy, as well as investigate
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the effect on several domains of health and nutrition in
the absence of pregnancy, as detailed elsewhere [21].
The WHO has not recommended antenatal MMN supplementation at this time [10]). The standard of care remains IFA supplementation, in spite of several large trials
that show that MMN supplementation is efficacious in
improving diverse health outcomes and meta-analyses that
have found that MMN supplementation could be more effective than IFA in preventing adverse pregnancy-related
health outcomes [12, 13]. Given that only around 50% of
anemia is suggested to be caused by low iron stores,
MMN supplementation could provide further benefit than
IFA alone [11]. Furthermore, improving stores from preconception could be of added benefit because adolescent
and young women would enter pregnancy with sufficient
pregnancy stores.
Overall, the MaPPS Trial is expected to offer insight
into providing an intervention that includes both LSBE
and MMN supplementation to adolescent and young
women from preconception and for a sufficient duration
of time, and on the impact on their infants. So as to
better understand the long-term effect of the intervention
on development (e.g., growth and neurodevelopment)
and diseases outcomes among infants born to study
participants, we anticipate conducting further follow
up studies in the future.
Trial status

As of May 2018, participants are still being enrolled in
the trial.
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